ARS Pharmaceuticals, Inc. (SPRY) stock

SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/30

$3.89+0.08 (+2.10%)

Close on Nov 13, 2026Market cap $386.85MP/E –Yield –

ARS Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

ARS Pharmaceuticals's EV/EBITDA was 5.5× on Jan 31, 2023.

Period	Period end	Value	Change (pts)
2023	Jan 31, 2023	5.5×	−2.3
2022	Dec 30, 2022	7.7×	–

Parsed from the XBRL in ARS Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SPRY.

Revenue growth-14.5% · median 110.0%

Operating margin-161.5% · median -56.2%

Net margin-163.6% · median -153.3%

Advertisement
300 × 250

See a number that looks wrong?